Meeting
2018 ASCO Annual Meeting
Liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) or gemcitabine plus cisplatin in advanced cholangiocarcinoma: The AIO-NIFE-trial, an open label, randomized, multicenter phase II trial.
Authors
Thomas Jens Ettrich
Ulm University, Ulm, Germany
Thomas Jens Ettrich , Andreas Wolfgang Berger , Thomas Seufferlein , Lukas Perkhofer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT03044587
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS4145)
DOI
10.1200/JCO.2018.36.15_suppl.TPS4145
Abstract #
TPS4145
Poster Bd #
327a
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
A single arm, prospective multicenter phase II study FOLFIRINOX in patients with advanced and recurrent biliary tract cancer.
First Author: Naminatsu Takahara
Poster
2020 Gastrointestinal Cancers Symposium
Phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2).
First Author: Benjamin Adam Weinberg
Poster
2014 ASCO Annual Meeting
Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine-based therapy.
First Author: Thomas H. Cartwright
Poster
2013 ASCO Annual Meeting
Updated use of first-line chemotherapy for advanced pancreatic cancer: Folfirinox versus gemcitabine.
First Author: Thomas H. Cartwright